Bayer Drug Pipeline

Bayer maintains a substantial clinical development portfolio, with 34 active trials out of 748 total registered trials since 2008. These active programs span from Phase 1 through Phase 4, with the greatest number in Phase 1 (15 trials), followed by Phase 3 (11 trials). The portfolio covers 16 therapeutic areas, but is heavily concentrated in Oncology, which accounts for 53% of active programs (18 trials). Within Oncology, the leading indications are Solid Tumor (Advanced) and Prostate Cancer, each with 7 active trials including one Phase 3 program apiece. Other therapeutic areas with ongoing clinical trials include Cardiovascular (5 active trials), Renal (3 active trials), Infectious Disease (2 active trials), Women's Health (1 active trial), and Rare Disease (1 active trial). The presence of 11 active Phase 3 trials suggests a pipeline with potential near-term catalysts.